RMC No. 59-2022 updates the VAT-exempt medicine list under CREATE to include certain cancer and COVID-19 treatment medicines.
Businesses selling, purchasing, prescribing, distributing, or accounting for qualified medicines for cancer and COVID-19 treatment must check whether their products are covered by the updated List of VAT-Exempt Medicines under Republic Act No. 11534, or the CREATE Act. RMC No. 59-2022 matters because it publishes the Food and Drug Administration endorsement updating the medicines treated as VAT-exempt, which directly affects pricing, invoicing, VAT reporting, and input-output VAT treatment for covered medicine transactions.
What Changed Under RMC No. 59-2022
RMC No. 59-2022 publishes the March 4, 2022 letter from the Food and Drug Administration of the Department of Health, through FDA OIC-Director General Dr. Oscar G. Gutierrez, Jr., endorsing updates to the List of VAT-Exempt Medicines under Republic Act No. 11534, otherwise known as the CREATE Act.
The key change is that the updated list now includes certain medicines for cancer and COVID-19 treatment. For businesses, this is not merely a health-sector advisory. It has tax consequences because the classification of a medicine as VAT-exempt affects whether 12% value-added tax should be passed on to the buyer, how sales should be recorded, and how the transaction should be reported in VAT returns and accounting records.
The practical issue for pharmacies, hospitals, clinics, distributors, importers, and corporate buyers is whether a specific medicine falls within the updated VAT-exempt list endorsed by the FDA. If the medicine is covered, the transaction should be treated consistently with VAT exemption rules applicable under the CREATE Act. If the medicine is not covered, the ordinary VAT treatment may still apply, depending on the nature of the taxpayer and transaction.
Who Is Most Affected
The taxpayers most affected by RMC No. 59-2022 are VAT-registered businesses engaged in the sale, purchase, distribution, importation, procurement, or administration of medicines, particularly those dealing with cancer medicines and COVID-19 treatment medicines. This includes drugstores, hospital pharmacies, healthcare institutions, medical distributors, pharmaceutical companies, wholesalers, and businesses with employee healthcare procurement programs.
Corporate accountants and CFOs should also pay attention to this issuance because the VAT treatment of covered medicines can affect billing, cost projections, tax compliance, and internal controls. A company purchasing medicines for employee health programs, a hospital billing patients for covered medicines, or a pharmacy selling covered medicines to the public must ensure that the VAT treatment applied is supported by the updated list.
The update is also important for in-house counsel and tax managers who review contracts with hospitals, HMOs, pharmaceutical suppliers, and procurement vendors. Where pricing clauses, tax gross-up provisions, or VAT-inclusive quotations are involved, the classification of medicines as VAT-exempt can affect the amount ultimately chargeable to patients, customers, or corporate buyers.
Key Compliance Requirement: Verify Coverage Before Applying VAT Exemption
The most important compliance step is verification. RMC No. 59-2022 does not announce a blanket VAT exemption for all medicines used in cancer or COVID-19 cases. It states that the updated List of VAT-Exempt Medicines now includes certain medicines for cancer and COVID-19 treatment. The word “certain” is critical. Businesses should not assume that every cancer-related or COVID-19-related medicine is automatically VAT-exempt.
Before treating a medicine sale as VAT-exempt, the taxpayer should confirm that the particular medicine is included in the updated list endorsed by the FDA. This verification should be done at the product level, not merely by therapeutic category. For example, an accounting department should not rely only on a general description such as “cancer medicine” or “COVID-19 medicine” without confirming that the specific medicine is covered by the updated list.
For invoicing and accounting purposes, businesses should align their point-of-sale systems, billing templates, enterprise resource planning systems, and tax codes with the updated VAT-exempt medicine list. If the tax setup is not updated, a business may either incorrectly charge VAT on exempt medicines or incorrectly remove VAT from medicines that are not covered.
Effective Date and Deadline Considerations
RMC No. 59-2022 was issued on April 27, 2022. The FDA endorsement referenced in the circular is dated March 4, 2022. Businesses reviewing historical transactions should take note of both dates when determining whether their VAT treatment, pricing, and accounting records are aligned with the updated VAT-exempt medicine list.
The issuance is especially relevant for businesses conducting tax reviews, BIR audit preparation, refund evaluations, or internal reconciliations involving medicine sales around the relevant period. Tax teams should identify transactions involving cancer and COVID-19 treatment medicines and determine whether the proper VAT treatment was applied based on the updated list.
Penalties and Audit Risks for Non-Compliance
RMC No. 59-2022 does not specify a special penalty for non-compliance. However, incorrect VAT treatment can still create ordinary tax risks under existing tax rules. A seller that improperly charges VAT on VAT-exempt medicines may face customer disputes, pricing issues, and possible tax reporting inconsistencies. A seller that improperly treats non-covered medicines as VAT-exempt may face deficiency VAT exposure in a BIR examination.
The practical audit risk is documentation. During a BIR review, it is not enough to state that a medicine is related to cancer or COVID-19 treatment. The taxpayer should be able to show why the transaction was treated as VAT-exempt, including reference to the updated list of VAT-exempt medicines endorsed by the FDA and published through RMC No. 59-2022.
Practical Steps for Businesses
Businesses should immediately review their medicine master list and identify products that may fall under cancer or COVID-19 treatment. Each product should be checked against the updated VAT-exempt medicine list. Once confirmed, accounting and billing systems should be updated so that covered medicines are properly coded as VAT-exempt.
Pharmacies, hospitals, and distributors should also train billing personnel and accounting staff to avoid blanket assumptions. The correct approach is product-specific verification. Internal tax teams should preserve documentation showing that the VAT-exempt treatment was based on the FDA-endorsed update published through RMC No. 59-2022.
For corporate buyers, especially those procuring medicines for employee health programs or institutional healthcare arrangements, procurement teams should request proper invoices and confirm whether VAT was correctly applied or excluded. If contracts or purchase orders quote VAT-inclusive prices, the parties should review whether pricing needs clarification when covered medicines are involved.
Why RMC No. 59-2022 Matters for VAT Compliance
RMC No. 59-2022 is important because VAT exemption affects both tax compliance and real-world medicine costs. For patients and institutional buyers, the proper application of VAT exemption may reduce the final cost of covered medicines. For sellers and distributors, the proper classification of covered medicines helps avoid invoicing errors and BIR audit exposure.
Common search issues connected with this issuance include VAT-exempt medicines Philippines, CREATE Act VAT exemption medicines, cancer medicines VAT exemption, COVID-19 medicines VAT exemption, and RMC 59-2022 VAT-exempt medicines. Businesses dealing with these products should treat the issuance as a compliance trigger, not merely as a reference document.
ASG Law Can Help with BIR and VAT Compliance
Ablola, Saribong & Gueco assists businesses, healthcare providers, distributors, pharmacies, and corporate taxpayers in reviewing VAT treatment, invoice compliance, BIR audit exposure, and tax documentation for regulated transactions. For companies dealing with medicines, healthcare products, or VAT-sensitive procurement, a product-level compliance review can help prevent costly tax errors.
For legal and tax assistance on RMC No. 59-2022, VAT-exempt medicines under the CREATE Act, BIR compliance, or tax audit preparation, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.